Zenagamtide
Metabolic / fat loss
Appetite, glucose, weight, and metabolic regulation
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Incretin / metabolic peptide or small molecule
- Primary mechanism
- Incretin/amylin/glucagon-axis receptor modulation
- Primary market use
- Metabolic / fat loss
Pharmacology
- Molecular weight (Da)
- 7846.60
- Oral bioavailability
- Route-dependent / verify
- Half-life
- ~12 h–7 days depending analog/acylation
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- MCE product listing / research chemical signal
- Clinical status
- Research chemical/reference listing
- Value-for-money score
- 8 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Stackability
Commonly compared/stacked in metabolic and body-composition protocols; verify redundancy and risk.
Notes
Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1 , amylin ( Amylin Receptor ) and calcitonin receptor ( Calcitonin Receptor ). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and a...